Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Jiangsu Lianhuan Pharmaceutical Co's Return-on-Tangible-Asset or its related term are showing as below:
SHSE:600513'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -3.33 Med: 5.65 Max: 6.59
Current: -3.33
During the past 13 years, Jiangsu Lianhuan Pharmaceutical Co's highest Return-on-Tangible-Asset was 6.59%. The lowest was -3.33%. And the median was 5.65%.
SHSE:600513's Return-on-Tangible-Asset is ranked worse than 69.98% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 3.085
vs SHSE:600513: -3.33
Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Jiangsu Lianhuan Pharmaceutical Co Return-on-Tangible-Asset Related Terms
Jiangsu Lianhuan Pharmaceutical Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Lianhuan Pharmaceutical Co Return-on-Tangible-Asset Chart
SHSE:600513 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Lianhuan Pharmaceutical Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Lianhuan Pharmaceutical Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Lianhuan Pharmaceutical Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Jiangsu Lianhuan Pharmaceutical Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 0.72% mean?
Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) has a Return-on-Tangible-Asset of 0.72% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors. This is 87% below median its historical median of 5.65. According to the industry distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #704 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 70%.
Is Jiangsu Lianhuan Pharmaceutical Co's Return-on-Tangible-Asset too high?
Jiangsu Lianhuan Pharmaceutical Co's current Return-on-Tangible-Asset of 0.72% is 87% below median its 10-year median of 5.65. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.09. Jiangsu Lianhuan Pharmaceutical Co's value of 0.72% is 76.7% below this industry median. Based on the distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #704 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Jiangsu Lianhuan Pharmaceutical Co has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Lianhuan Pharmaceutical Co's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #704 out of 1006 companies for Return-on-Tangible-Asset. This places Jiangsu Lianhuan Pharmaceutical Co in the lower half of its industry. The industry median Return-on-Tangible-Asset is 3.09. Jiangsu Lianhuan Pharmaceutical Co's value of 0.72% is 76.7% below this benchmark. While the company's 10-year median is 5.65 vs. the industry median of 3.09, Jiangsu Lianhuan Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.09, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Lianhuan Pharmaceutical Co's current Return-on-Tangible-Asset of 0.72% is 76.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Lianhuan Pharmaceutical Co's current Return-on-Tangible-Asset is 0.72%, which is 87% below median its own 10-year median of 5.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Lianhuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥13.83, compared to a current price of ¥16.64 — trading 20.3% above its estimated fair value. The current Return-on-Tangible-Asset is 0.72%, which is 87% below median its 10-year median of 5.65 and 76.7% below the Drug Manufacturers industry median of 3.09. Jiangsu Lianhuan Pharmaceutical Co's overall GF Score™ is 63/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513), the current Return-on-Tangible-Asset is 0.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥16.64 is trading 20.3% above its estimated GF Value™ of ¥13.83.
GuruFocus considers Jiangsu Lianhuan Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:600513:
Return-on-Tangible-Asset: 0.72% (87% below median its 10-year median of 5.65)
GF Value™: ¥13.83 vs. price of ¥16.64 (20.3% above fair value)
Industry Position: 76.7% below the Drug Manufacturers median (#704 of 1006)
No single metric tells the full story. See the SHSE:600513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs. In the field of pharmaceutical manufacturing, the company's main products include several series such as urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics, etc., covering chemical raw materials and injections, solid preparations and various drug dosage forms, including the national first-class new drug Apelite Tablets (Chuanliu).
63GF Score
Get the complete analysis for SHSE:600513
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600513 has been successfully added to your 
